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Abstract 
 
Background 
Urine culture at the point of care minimises delay between obtaining the sample and agar inoculation 
in a microbiology laboratory, and quantification and sensitivity results can be available more rapidly in 
primary care. 
Objective  
To identify the degree to which clinicians’ interpretations of a point-of-care-test (POCT) urine culture 
(Flexicult
TM 
SSI-Urinary Kit) agrees with laboratory culture in women presenting to primary care with 
symptoms of uncomplicated urinary tract infections (UTI). 
 
Methods 
Primary care clinicians used the Flexicult
TM
-POCT, recorded their findings and took a photograph of 
the result, which was interpreted by microbiology laboratory technicians. Urine samples were 
additionally processed in routine care laboratories. Cross tabulations were used to identify important 
differences in organism identification, quantification and antibiotic susceptibility between these three 
sources of data. The influence of various laboratory definitions for UTI on culture were assessed. 
 
Results 
Primary care clinicians identified 202/289 urine samples (69.9%) as positive for UTI using the 
Flexicult
TM
-POCT, whereas laboratory culture identified 94-190 (32.5-65.7%) as positive, depending 
on definition thresholds. 82.9% of samples identified positive for E. coli on laboratory culture were also 
considered positive for E. coli using the Flexicult
TM 
-POCT, and susceptibilities were reasonably 
concordant. There were major discrepancies between laboratory staff interpretation of 
Flexicult
TM
 photographs, clinicians’ interpretation of the Flexicult
TM
 test, and laboratory culture results. 
 
Conclusion 
Flexicult
TM
-POCT overestimated the positivity rate of urine samples for UTI when laboratory culture 
was used as the reference standard. However, it is unclear whether point-of-care or laboratory based 
urine culture provides the most valid diagnostic information. 
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Keywords Urinary tract infection, Primary Health Care, Point of Care Test, Adult women, Antibiotic 
resistance, Diagnosis      
 
  
Background 
Nearly 40% of women suffer from symptoms of urinary tract infection (UTI) in their lifetime and UTIs 
account for about 15% of antibiotic prescriptions in primary care.
1,2
 The majority of symptoms 
attributed to UTIs in otherwise healthy women presenting to primary care are accounted for by 
uncomplicated episodes of acute cystitis and urethritis. Nevertheless, they have a major impact on 
quality of life.
3
  In line with current general practice guidelines, women with typical UTI  symptoms are 
usually treated empirically without additional diagnostic testing.
4,5
 This may result in both inappropriate 
and unnecessary antibiotic use.  
Antibiotic resistance, especially in Gram-negative organisms that cause most UTIs, is increasing and 
is associated with antibiotic use. 
6
 The World Health Organization considers antimicrobial resistance to 
be one of the three greatest threats to human health. 
7
 Therefore, strategies to better target antibiotics 
to those who are most likely to benefit are needed.  
There is currently no international gold standard for the microbiological diagnosis for UTI, including no 
consensus about the quantification of bacteria on urine culture that confirms a UTI.
8
   General 
practitioners (GPs) frequently use a point of care test (POCT) such as urine dipstick or dip-slides. 
However, these approaches neither predict antibiotic response nor indicate antibiotic susceptibility, 
which are important to guide appropriate choice of antibiotic class.  
The Point of Care Testing for Urinary Tract Infection in Primary Care (POETIC) study evaluated a 
modified version of the Flexicult
TM
 SSI-urinary kit a POCT urine culture test that is already in wide use 
in Denmark. 
9,10
 Flexicult
TM
 is an overnight point of care test (POCT), which can provide GPs with 
organism identification, quantification and antibiotic sensitivities within 24 hours.  The POETIC trial 
aimed to determine whether a POCT used at the point of care could improve targeting of antibiotic 
therapy and patient outcomes in uncomplicated UTI. 
Performing urine culture at the point of care reduces delay between obtaining the sample and agar 
inoculation following receipt of urine in a laboratory, and obtaining a report of the identification, 
quantification and sensitivity results from the laboratory. However, the degree to which GPs’ 
interpretations of the POCT agree with laboratory interpretation of the POCT results and routine 
laboratory culture is unknown. We used the opportunity of the POETIC Trial of the effect of the 
Flexicult
TM
 POCT in routine care to identify discrepancies between point of care and laboratory urine 
culture in women presenting to primary care with symptoms of uncomplicated UTI.  
Methods  
Participants 
All data came from participants of the POETIC randomised controlled trial. 
10
  Women were recruited 
from primary care research networks in four countries (Wales, England, Spain and the Netherlands) 
between June 2013 until September 2014. They were randomised to receive treatment guided by 
Flexicult
TM
, or standard care. Only data from the participants randomised to the Flexicult
TM
 care arm 
are included in this analysis. The design and rationale of POETIC trial are described elsewhere.
10
 
Briefly, eligible patients were adult women aged 18 years and older presenting to primary care with at 
least one of three key urinary tract symptoms (dysuria, urgency and frequency) and where the GP 
suspected an uncomplicated UTI. Exclusion criteria at baseline were women who were either 
terminally ill, were receiving treatment for life-threating cancer, were having severe systemic 
symptoms or had received antibiotics for UTI within the past four weeks. Informed, written consent 
was obtained from all the participants. The trial was approved by the Research Ethics Committee for 
Wales recognised by the United Kingdom Ethics Committee Authority and also approved by the 
relevant local Governance Committees in the Netherlands and Spain.   
Primary objective of the present analysis 
Three assessments of urine culture results were available: 1) Primary care clinicians’ record of their 
interpretation of Flexicult
TM
 results; 2) Laboratory staff interpretations of photographs of the Flexicult
TM
 
taken by clinicians at the time of their interpretation; and 3) routine microbiology laboratory culture 
results. The primary objective of the current analysis was to identify potentially clinically important 
differences in organism identification, quantification, sensitivity and culture growth between the 
clinicians’ interpretation’ of Flexicult
TM
, laboratory staff’ interpretations of photographs of Flexicult
TM
, 
and the laboratory culture results. 
Urine sampling procedures 
Flexicult
TM
 is designed for use in primary care and is essentially an agar plate with higher sides, 
divided into six sections and containing chromogenic agar. In addition to culturing bacteria (for 
bacterial quantification) and identification, antibiotic susceptibility of bacteria is determined through 
observing growth in sections which are impregnated with commonly used antibiotics (figure 1). The 
larger section allows for identification and quantitative analysis, and 5 smaller sections for antibiotic 
susceptibility testing. There were differences in the antibiotics incorporated into the Flexicult
TM
 POCT 
to reflect local differences in antibiotics commonly prescribed for UTI in each country (figure 1).  
Clinicians were provided with face to face training as part of POETIC, a country specific Flexicult
TM
 
brochure, and a poster to aid interpretation of results. Mid-stream urine samples were collected using 
a urine collection device (Peezy Midstream, Forte Medical). A fraction of this urine sample was sent by 
post in a universal tube containing boric acid to laboratories assigned to the POETIC study in each 
country, and the remainder was used to inoculate the Flexicult
TM  
POCT culture plate. The results of 
Flexicult
TM
 were documented by the clinicians after overnight (18-24 hours) incubation in a benchtop 
incubator at a temperature of 35-37ºC. Bacterial growth was recorded (i.e. no growth, pure growth or 
mixed growth of an organism, and if mixed growth then presence of predominant growth). Bacterial 
quantification assessed the number of colonies (less than 15 colonies, 15-20 colonies corresponding 
to ≤10e3 CFU/mL, ≥20 colonies corresponding to 10e3-10e5 CFU/mL, semi confluent/confluent 
growth corresponding to ≥10e5 CFU/mL). Clinicians compared the colony colour and morphology of 
their plate to example illustrations in the Flexicult
TM
 brochure to identify organisms. If bacterial growth 
was assessed at ≥10e3 CFU/mL of a pure or predominant organism, then clinicians were asked to 
record antibiotic susceptibility. Clinicians also photographed the Flexicult
TM
 plates at the time of their 
assessment. 
 
The photographs of Flexicult
TM
 plates were interpreted independently by two experienced UK 
microbiology laboratory staff blind to clinicians’ interpretations and laboratory culture findings. The staff 
conferred with a senior microbiologist when discrepancies occurred (<1%, usually due to poor 
resolution in pictures) and provided a consensus result.  
Urine samples were processed by culturing 50uL of urine onto chromogenic agar (Oxoid, Poole, UK) 
using spiral plater (Don Whitley, UK). Plates were incubated for 20 hours then viable counts of all 
species present taken. Pure or predominant organisms were identified using MALDI-ToF (Bruker, 
Germany) with the background organism identification estimated from the chromogenic agar. Antibiotic 
susceptibility was determined by agar dilution using EUCAST breakpoints.      
Definition of positive UTIs 
There is currently no strict consensus concerning thresholds for a laboratory definition of a UTI. 
Therefore, several common definitions for a positive microbiological UTI diagnosis were considered for 
this analysis.  
Flexicult
TM 
definition of a UTI
: 
  
o  ≥10e3 CFU/mL, pure culture of a urinary tract pathogen 
o ≥10e3 CFU/mL, predominant growth of urinary tract pathogen in mixture with normal flora 
Three Laboratory culture definitions of a UTI: 
1. European guidelines definition of a UTI
11
: 
§ 10e3 CFU/mL of a uropathogen is diagnostic in women who present with 
symptoms of acute uncomplicated cystitis 
2. Public Health England(PHE)/Health Protection Agency guidelines(HPA) definition
20
  
§ ≥10e4 CFU/mL, pure culture of a pathogen  OR 
§ ≥10e5 CFU/mL, mixed growth with one predominant pathogen OR 
§ ≥10e3 CFU/mL, growth of either E. coli or S. saprophyticus 
3. UK laboratory definition 
§ ≥ 10e5 CFU/mL, pure culture of a uropathogen OR 
§ ≥ 10e5 CFU/mL, predominant culture a uropathogen with 3 log difference 
between highest and next species 
 
Statistical analysis 
Urine results were compared in three ways; 1) the routine laboratory culture results versus the 
clinicians’ interpretation of Flexicult
TM
 (‘Lab vs Flexicult
TM
’); 2) the clinicians’ interpretation of 
Flexicult
TM
 versus the laboratory staff’s interpretation of the Flexicult
TM
 photographs (‘Flexicult
TM
 vs 
Photo’); and, 3) the routine laboratory culture results versus the UK microbiology laboratory staff’s 
interpretation of the Flexicult
TM
 photographs (‘Lab vs Photo’). Further exploration focused on the 
laboratory culture results and the clinicians’ interpretation of Flexicult
TM
 results (‘Lab vs Flexicult
TM
’).  
Only cases with complete data in both the groups for that specific variable (i.e. threshold growth, purity 
of bacterial growth) were used. Flexicult
TM
 defined growth of one organism 10 times greater than any 
other as predominant, whereas the laboratory used 1000 times greater as predominant. Cross 
tabulation with Cohen’s kappa estimates were compared for the three groups. Concordance of the 
identified organisms, susceptibility results and agreement in the diagnosis of UTI were only analyzed 
between the laboratory cultures and the Flexicult
TM
 cultures. Prevalence Adjusted Bias Adjust kappa 
(PABAK
12
) values were estimated. When only small numbers were available (i.e., n≤10) for a 
susceptibility testing results for a particular antibiotic, this antibiotic was excluded for further analysis.  
To assess significant discrepancies in resistance rates, p-values were calculated using McNemar’s 
test and Bonferroni adjustments were made. Statistical analyses were performed with SPSS version 
22.0 (SPSS Inc, Chicago, ILL, USA).  
Results 
In all, 643 patients were recruited into the POETIC Trial, and 325 patients were randomised to the 
Flexicult
TM
 arm. Results from the Flexicult
TM
 were recorded for 312 (96.0%) participants (Figure 2). All 
included participants were female, their mean age was 49 years, 85.4% had a history of UTI, 68.6% 
were from the UK, 27.1% from Spain, and 4.2% from the Netherlands. In the UK and the Netherlands, 
the Flexicult
TM 
plates were read by either GPs, nurses or other health care professionals. In Spain, the 
Flexicult
TM
 plates were read only by GPs. 
Purity of growth and bacterial quantification  
The purity of bacterial growth in Flexicult
TM 
was compared with the purity of growth on routine culture 
media in the laboratory for 294 corresponding urine samples (Table 1).  Overall, there was a very low 
level of inter-rater agreement (Kappa = 0.06 (95%CI 0.000-0.122)).  There were particularly marked 
discrepancies within the mixed growth categories. 
There were fewer samples with bacterial counts of ≥10e3 CFU/mL in the laboratory culture (182/276) 
compared to Flexicult
TM
 (204/276). The concordance between the laboratory culture and Flexicult
TM
 
was similar for the urine samples with colony counts of  ≤10e3 CFU/mL (34.0%) and colony counts of  
10e3-10e5 CFU/mL (34.6%), but concordance was only  58.7% for the urine samples with colony 
counts of  ≥10e5 CFU/mL. 
 
There were important discrepancies in laboratory staff interpretation of the photographs of Flexicult
TM
 
plates compared to clinicians’ interpretation of Flexicult
TM
 and compared to routine culture results with 
respect to both purity of growth and bacterial quantification (Supplementary table S1). 
The subsequent analyses focuses only on the comparison of the laboratory culture results and the 
clinicians’ interpretation of Flexicult
TM
 results (‘Lab vs Flexicult
TM
’).   
Organism identification  
In routine laboratory culture, pure or predominant uropathogens were isolated with quantitative counts 
of ≥10e3 CFU/mL in 124/287 samples. The most commonly isolated species was E. coli (75.8%), 
followed by S. saprophyticus (5.6%). In contrast, Flexicult
TM
 identified 200/287 (69.7%) pure or 
predominant uropathogens with quantitative counts of  ≥10e3 CFU/mL. E. coli accounted for 58.0% of 
bacterial species isolated with Flexicult
TM
, followed by Enterococcus (20.0%). Overall, 82.9% of 
pure/predominant E. coli with quantitative counts of ≥10e3 isolated by routine culture (reference test) 
were also identified by Flexicult
TM
.  
 
Antimicrobial susceptibility results.  
Flexicult
TM
 identified E. coli in 63 urine samples (Table 2). Laboratory culture found no resistance to 
nitrofurantoin, fosfomycin or cefuroxime. Therefore, statistical analysis for laboratory culture and 
Flexicult
TM
 could not be done. Resistant pathogens were more common according to Flexicult
TM
 
compared to laboratory culture. The accuracy of the susceptibility testing in Flexicult
TM
 varied from 
81.0 % for amoxicillin/clavulanate to 96.6% for ciprofloxacin using laboratory susceptibility analysis as 
the reference standard. Kappa scores ranged from 0.49 to 0.60, which indicates a ‘moderate’ level of 
agreement. PABAK scores, calculated to adjust for the prevalence and bias, showed ‘good’ to ‘very 
good’ agreement (0.60-0.94) between Flexicult
TM
 and laboratory culture for all the analysed antibiotics.  
Amoxicillin and cephalothin susceptibility results were excluded from analysis due to small numbers 
(n≤10). 
 
UTI diagnosis 
Flexicult
TM
 resulted in 202 samples (69.9%) being classified as positive for a UTI. The proportion of 
positive samples on laboratory culture varied according to the definition used, but all definitions 
resulted in a lower proportion than was identified using Flexicult
TM
. The European guidelines 
definition
11
  identified 190 positive samples (65.7%) as UTI, HPA/PHE definition
13
 resulted in 137 
(47.4%) positive samples, and the UK laboratory definition resulted in 94 (32.5%) positive samples. 
Table 3 shows the number of concordant and discordant samples along, with agreement measures. 
Flexicult
TM
 identified false positives for UTI of between 21.4-44.3%, and false negatives of between 
6.9-17.3%, sensitivity of between 73.7% -78.8% (95%CI 66.8-79.8, 95% CI 71.0-85.3) and specificity 
of between 34.4-38.1% (95%CI 27.7-41.5, 95%CI 30.4-46.4) when compared to the various laboratory 
thresholds for UTI. The agreement values were all poor (Table 3).  
 
Discussion  
The aim of this study was to describe potentially important discrepancies between Flexicult
TM
 POCT 
urine culture results, their corresponding photograph, and the corresponding laboratory urine culture 
results for urine samples obtained from women presenting to their primary care practice with 
symptoms of a UTI. We found that Flexicult
TM
 POCT and laboratory urine routine culture had poor 
levels of agreement in identifying microbiologically positive urine samples. Flexicult
TM
 tended to 
overestimate the positivity rate for a urine sample taken for UTI when laboratory culture was used as 
reference standard.  Moreover, we identified important discrepancies regarding bacterial quantification 
and purity of growth between Flexicult
TM
 and laboratory culture, especially for determining 
predominant growth.  However, Flexicult
TM
 compared to laboratory culture identified the vast majority 
(82.9%) of E. coli correctly and the susceptibility testing results were reasonably concordant for 
ciprofloxacin, amoxicillin/clavulanate and trimethoprim. GPs were more likely to overcall the “no 
growth” result, mainly to denote no significant growth. This did not impact upon diagnosis of UTI. 
 
Blom et al.
9
 analysed results from Flexicult
TM
 plates compared to laboratory cultures from 121 patients 
in Danish primary care with suspected UTI, and found an error rate of 16% for quantification and an 
error rate of <7% for antibiotic susceptibilities. However, purity of growth was not analysed.  Bongard 
et al.
14
 compared laboratory urine microscopy and culture with findings from UK Flexicult
TM
 plates for 
200 urine samples submitted routinely from hospital and primary care patients to a hospital 
microbiology laboratory. There was an error rate of 16.5% in defining a urine sample UTI positive.
14
 
This compares to the error of 38.8%-51.2% that we found, which may have arisen because only one 
observer read all of the plates in the Bongard study compared to many clinicians reading only a small 
number of plates each in the less controlled environment of clinical practice. Moreover, different 
criteria for the laboratory definition of UTI were used. The Danish Flexicult
TM
 study based their 
definition only on bacterial quantification ≥10e3 CFU/mL, whereas Bongard et al. used a bacterial 
quantification threshold ≥10e5 CFU/mL and also took the purity of the organisms (i.e. 
pure/predominant) into account. This is in line with our findings that changing the definitions influences 
the numbers of apparent false negative or false positive results by Flexicult
TM
.  
Traditionally, growth of ≥10e5 CFU/mL of uropathogens from urine has been considered to indicate a 
microbiologically defined UTI. However, previous studies demonstrated that urine samples from 
symptomatic women with pyuria often contain bacterial growth of ≤10e5 CFU/mL.
15,16
  
Three other culture based POC UTI diagnostic tests have been assessed (i.e. Uricult Trio
17
, 
DipStreak
18
, Diaslide
19
), which have be shown to have high sensitivity (≥88%) and specific (≥90%) for 
diagnosing a UTI when compared to laboratory culture, although confidence intervals were not 
reported and antibiotic susceptibility was not analysed. 
 Since all patients included in the POETIC trial had symptoms attributable to UTI, the low prevalence 
of urine samples meeting the HPA/PHE and UK laboratory criteria for UTI is unexpected, and may 
indicate that laboratory culture results in high false negative rates or that there were other (non-
infectious) causes of the symptoms. UTI prevalence similar to Flexicult
TM
 was found when a lower 
threshold, for example the European guideline definition, was used.  Concordance between the 
laboratory cultures and Flexicult
TM
 for no growth was low (18%), which could be explained by changes 
in viable bacteria in urine samples between the time the sample was taken and when it was analysed 
in the laboratory.   
 
Strengths of our study include the sample size, the ability to compare results by various definitions of a 
UTI on culture, and the independently interpretation of the photographs. There are also several 
limitations.  First, the photographs of Flexicult
TM
 plates were interpreted independently by two 
experienced UK microbiology laboratory staff blind to clinician’s interpretations and laboratory culture 
findings.  However, the GPs were more likely to overcall pure or predominant growth – they were less 
likely to note the presence of other bacteria in the culture. Microbiologists are trained to look for this 
and so may have been more adept at identifying mixed cultures. Overcalling pure and predominant 
growth would account for the higher UTI prevalence within the GP interpretations. This could lead to 
over-prescribing of antibiotics in primary care if one assumes that the laboratory results more often 
both correctly identifies and correctly rules out UTIs. On the other hand, because Flexicult
TM
 is based 
on fresher urine samples and may be interpreted in conjunction with clinical findings, it may provide a 
more accurate estimate of true positive and true negative UTIs.
20  
 Secondly, there were major 
disagreements between laboratory staff interpretation of Flexicult
TM
 photographs compared to 
clinicians’ interpretation of Flexicult
TM
 and routine culture results. Whilst the reasons for these 
differences are not clear, they may relate to  errors in the clinicians understanding or interpretation as 
well as the quality of the photographs. Until the reasons for such discrepancies are clearer, 
photographs of Flexicult
TM
 plates should neither be considered as a reliable diagnostic device nor as a 
useful tool for quality assurance.  Thirdly, predominant growth of uropathogens differed markedly 
between findings from Flexicult
TM
 and laboratory culture, which may be due the different criteria used 
for determining predominant growth. Furthermore, Flexicult
TM 
tended to overestimate antibiotic 
resistance, which could lead to GPs prescribing more broad spectrum antibiotics. However, the 
differences were not significant and prescribing a broad-spectrum antibiotic instead of a narrow 
spectrum antibiotic when organisms are resistant could benefit patients in the short term. However, 
over prescribing of broad spectrum antimicrobials is the most common cause of resistance 
development.  Finally, discrepancies between laboratory culture in five different laboratories may have 
contributed to the overall lack of concordance. Clinicians who interpreted Flexicult
TM
 plates would have 
had limited experience in doing so, and clinicians only had approximately an hour of training in 
Flexicult
TM
 interpretation 
Conclusion and clinical implications 
Overall, our findings suggest Flexicult
TM 
used in the context for routine primary care, provides 
information that differs in important ways from laboratory culture especially regarding quantification. 
The value of Flexicult
TM
 in diagnosing UTI remains unclear, but we found reasonable evidence for its 
value in antibiotic susceptibility testing, and this could be used before prescribing antibiotics, for 
example in deciding on which antibiotic to use for either an immediate or delayed prescription once a 
decision has been made to consider antibiotics. Future studies that correlate diagnostic test results (at 
various thresholds) with symptoms and response to treatment are urgently required in order to 
determine both the most accurate criteria for defining a positive UTI on urine culture, and to determine 
whether near patient tests provide a more accurate guide to symptomatic benefit from antibiotic 
treatment.  
 
.  
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 Table 1 Cross tabulation of GP interpretation of Flexicult
TM
 plate (Flexicult
tm) 
 versus laboratory 
culture  in respect with the bacterial quantification and purity of growth (either no growth, pure 
growth or mixed growth)). 
Abbreviations : pred, predominant 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Threshold 
growth 
n=276 
Laboratory   
<10e3 
CFU/mL 
10e3-
10e5 
CFU/mL 
>10e5 
CFU/m
L 
Total 
Flexicult
TM
 
<10e3 
CFU/mL 
32 20 20 72 
10e3-10e5 
CFU/mL 
38 27 23 88 
≥10e5 
CFU/mL 
24 31 61 116 
Total 94 78 104 276 
Statistical measurements   
Kappa (95%CI)    0.147 (0.061-0.233) 
Error rate       57%   
Bacterial 
growth 
n=294 
Laboratory
 
 
No 
growth 
Mixed 
not 
pred.   
Mixed 
pred. 
Pure 
grow
th 
Total 
Flexicult
TM
     
No growth 8 9 3 15 35 
Mixed growth 
(Not predominant) 
3 4 3 6 16 
Mixed growth 
(Predominant) 
10 37 7 37 91 
Pure growth 23 34 11 84 152 
Total 44 84 24 142 294 
Statistical measurements   
Kappa (95%CI) 0.06 (0.000-0.122)   
  Error rate 65%     
Table 2 Susceptibility results for both the Flexicult
TM 
 test and the laboratory cultures for the 
cases  in which Escherichia coli was correctly identified by the Flexicult
TM 
. 
 
 
amoxi/clavula
 
n=58 
Laboratory culture 
Sensitive Resistant Total 
Flexicult
TM 
    Sensitive 
 
39 
 
2 
 
41 
    Resistant 9 8 17 
    Total 48 10 58 
Resistance rate Lab:    17% 
Resistance rate Flex:   29%     p-value 0.065 
Sensitivity (95%CI) 80 (44.4-97.5) 
Specificity (95% CI) 81 (67.4-91.1) 
PPV 47 (23.0-72.2) 
NPV 95 (83.5-99.4) 
Error rate (%) 19% 
Kappa (95%CI) 0.48(0.227-0.732) 
PABAK 0.62 
ciprofloxacin 
n=58 
Laboratory culture 
Sensitive Resistant Total 
Flexicult
TM 
    Sensitive 
 
55 
 
0 
 
55 
    Resistant 2 1 3 
    Total 57 1 58 
Resistance rate Lab:     2% 
Resistance  rate Flex:   5%   p-value 0.500 
Sensitivity (95%CI) 100 (2.50-100.0) 
Specificity (95% CI) 96 (87.9-99.6)  
 
PPV 33 (0.84-90.6) 
NPV 100 (93.5-100.0) 
Error rate (%) 3% 
Kappa (95%CI) 0.49(-0.113-1.087) 
PABAK 0.94 
nitrofurantoin 
n=52 
Laboratory culture 
Sensitive Resistant total 
Flexicult
TM 
    Sensitive 
 
47 
 
0 
 
47 
    Resistant 5 0 5 
    Total 52 0 52 
Resistance rate Lab: 0% 
Resistance  rate Flex: 10%    
Statistical measurements: - * 
trimethoprim 
n=35 
Laboratory culture 
Sensitive Resistant total 
Flexicult
TM 
    Sensitive 
 
27 
 
3 
 
30 
    Resistant 1 4 5 
    Total 28 7 35 
Resistance rate Lab: 20% 
Resistance  rate Flex: 14 %   p-value 0.625 
Sensitivity (95%CI) 57.1 (18.4-90.1) 
Specificity (95% CI) 96.4 (81.6-99.0) 
PPV 80.0 (28.4-99.5) 
NPV 90.0 (73.5-97.9) 
Error rate (%) 11% 
Kappa (95%CI) 0.60 (0.249-0.951) 
PABAK 0.78 
fosfomycin 
n=21 
Laboratory culture 
Sensitive Resistant Total 
Flexicult
TM 
     Sensitive 
 
18 
 
0 
 
18 
     Resistant 3 0 3 
     Total 21 0 21 
Resistance rate Lab: 0% 
Resistance  rate Flex: 14 %    
Statistical measurements: - * 
cefuroxime 
n=20 
Laboratory culture 
Sensitive Resistant Total 
Flexicult
TM 
    Sensitive 
 
17 
 
0 
 
17 
    Resistant 3 0 3 
    Total 20 0 20 
Resistance rate Lab: 0% 
Resistance  rate Flex: 15%    
Statistical measurements: - * 
Abbreviations: Lab, Laboratory; Flex, Flexicult
TM
; PPV, positive predictive value; NPV, negative 
predictive value, PABAK, Prevalence Adjusted Bias Adjust Kappa. * Due to no resistance rate in 
laboratory culture further statistics are not calculated.   
Table 3 Cross tabulation of Flexicult
TM
 versus laboratory cultures (with the different thresholds) in determining urinary tract infections (n=289).  
3A Flexicult
TM 
versus EUCAST >10e3 definition of UTI;  3B Flexicult
TM 
versus PHE/HPA definition of UTI; 3C Flexicult
TM 
versus UK laboratory definition of UTI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UTI Yes/No 
n=289 
European >10
e
3 
definition 
Yes UTI No UTI Total 
Flexicult
TM 
Yes UTI 
 
140 
48%) 
 
62 
(21%) 
 
202 
No UTI 50 
(17%) 
37 
(13%) 
87 
Total 190 99 289 
Statistical measurements 
Sensitivity 
(95%CI) 
73.7 (66.8-79.8) 
Specificity (95% 
CI) 
 37.4 (27.9-
47.7) 
 
 
PPV 69.3 (62.5-75.6) 
NPV 42.5 (32.0-53.6) 
Error rate (%) 39% 
Kappa (95%CI) 0.11(-0.008-0.232) 
PABAK 0.22 
UTI Yes/No 
n=289 
PHE/HPA definition 
 
Yes UTI No UTI Total 
Flexicult
TM
  
Yes UTI 
 
108 
(37%) 
 
94 
(33%) 
 
202 
No UTI 29 
(10%) 
58 
(20%) 
87 
 Total 137 152 289 
Statistical measurements 
Sensitivity 
(95%CI) 
78.8 (71.0-85.3) 
Specificity (95% 
CI) 
38.1 (30.4-46.4)  
 
PPV 53.5 (46.3-60.5) 
NPV 66.7 (55.8-76.4) 
Error rate (%) 43% 
Kappa (95%CI) 0.17 (0.07-0.27) 
PABAK 0.14 
UTI Yes/No 
n=289 
UK laboratory definition 
 
Yes UTI No UTI Total 
Flexicult
TM 
Yes UTI 
 
74 
(26%) 
 
128 
(44%) 
 
202 
No UTI 20 (7%) 67 
(23%) 
87 
Total 94 195 289 
Statistical measurements 
Sensitivity 
(95%CI) 
78.7 (69.1-86.5) 
Specificity (95% 
CI) 
34.4 (27.7-41.5)  
 
PPV 36.6 (30.0-43.7) 
NPV 77.0 (66.8-85.4) 
Error rate (%) 51% 
Kappa (95%CI) 0.10 (0.02-0.18) 
PABAK 0.02 
Abbreviations:	PHE/HPA,	Public	Health	England/Health	Protection	Agency;	UTI,	urinary	tract	infection;	PPV,	positive	predictive	value;	NPV,	negative	predictive	value,	
PABAK,	Prevalence	Adjusted	Bias	Adjust	Kappa.	
			
3A	 3B	3C	
  
Figure 1. The UK Flexicult SSI-Urinary Kit 
* Spain: Fosfomycin instead of Trimethoprim, Cefuroxime instead of Cephalothin 
** Netherlands: Amoxicillin instead of Cephalothin 
 
 
Figure 2. Flowchart of the cases evaluated in the study 
Abbreviations:  CRF, case report form; UTI, urinary tract infection.	
 
 
